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Asthma and COPD are two diseases related to eosinophils. But at present, we do 
not know with certainty how much these cells participate in these diseases, beyond 
that the treatment of the underlying cause produces the resolution of eosinophilia 
in a “reactive” way. Eosinophil-related diseases are a spectrum of systemic diseases 
such as Asthma and COPD in pneumology area. Under inflammatory conditions, 
the number of circulating eosinophils or tissues can increase dramatically, with 
rapid development of eosinophilia and we can obtain in a simple laboratory test. 
In general, the number of eosinophils in the blood can provide useful information 
and considering the differential diagnosis and for the subsequent test of patients 
presenting with eosinophilia. The treatment of eosinophilia currently in number of 
300 cells in which is the criteria and the target to be treat. The best known and most 
used of all treatments for diseases related to eosinophils are corticosteroids, which 
decrease circulating and tissue eosinophils in a few hours, through mechanisms 
that include the direct activation of eosinophil program death. Targeted treatment 
against eosinophils could improve airway remodeling through mechanisms that 
are not fully known, and their effects on lung function are variable and decreasing 
symptoms in patients.
Keywords: eosinophil, asthma, COPD
1. Introduction
Asthma and COPD are two diseases related to eosinophils in which eosinophils 
are the main cause and journals have evidence an increase in their number in the 
blood with or without evidence of their activation. But at present, we do not know 
with certainty how much these cells participate in these diseases, beyond that 
the treatment of the underlying cause produces the resolution of eosinophilia in 
a “reactive” way. Eosinophil-related diseases are a spectrum of systemic diseases 
such as Asthma and COPD in pneumology area. Even within the principal dis-
eases related to eosinophils, the location, type of tissue involved, and magnitude 
of eosinophilia vary greatly. Under inflammatory conditions, the number of 
circulating eosinophils or tissues can increase dramatically, with rapid develop-
ment of eosinophilia and we can obtain in a simple laboratory test. In general, the 
number of eosinophils in the blood can provide useful information and consider-
ing the differential diagnosis and for the subsequent test of patients presenting 
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with eosinophilia. Currently eosinophils has taken a very important role in the 
treatment of severe diseases, we know are so prevalent and increased morbidity 
and mortality in serious phases which produce a lower quality of life in patients, 
the treatment of eosinophilia currently in number of 300 cells in which is the 
criteria and the target to be treat. The best known and most used of all treatments 
for diseases related to eosinophils are corticosteroids, which decrease circulat-
ing and tissue eosinophils in a few hours, through mechanisms that include the 
direct activation of eosinophil program death. But, under certain circumstances, 
eosinophils can become resistant to these drugs or in the presence of high levels of 
eosinophil survival cytokines, such as IL-5 by example. With the administration 
of anti-IL-5 antibodies, such as mepolizumab or reslizumab the blood eosinophils 
typically decrease by at least 80% within a few days, without decreasing them 
much in the tissues, such as in the lower airways. Asthma, presumably due to 
the action of other eosinophil cytokines, such as GM-CSF, present in tissues. 
Comparatively, the administration of benralizumab, an anti-IL-5 antibody that 
acts on the IL-5 receptor, causes a much deeper and longer decrease in eosino-
phils, by activating antibody-dependent cellular cytotoxicity. Targeted treatment 
against eosinophils in eosinophilic asthma and eosinophilic COPD decreases 
exacerbations and could improve airway remodeling through mechanisms that are 
not fully known, and their effects on lung function are variable and decreasing 
symptoms in patients.
Data from multiple studies in asthma and eosinophilic COPD suggest that they 
are safe long-term drugs despite the decrease in eosinophils over time, as well as 
being well tolerated. Eosinophils exist in virtually all vertebrates as part of the 
innate immune system, which underscores the important benefits they must pro-
vide to their guests. In humans, they are in normal ranges when their blood levels 
are <500 / μL, although this number can vary between 350 to 600 depending on the 
laboratory. Eosinophilia is defined when its number is>300/μL in the recent studies 
and guidelines. [1–2]
2. Eosinophil hematopoiesis
For eosinophils to develop, a unique set of transcription factors is required, 
which if not present, do not develop (Figure 1). Similarly, the eosinophil lineage 
Figure 1. 
The eosinophil.
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depends on the appearance of a specific receptor on its surface for IL-5. The 
expression on the cell surface of the IL-5 receptor is one of the first events for 
the development of the specific eosinophil lineage that occurs in the bone mar-
row, although recent data in rats suggest that another cytokine, the IL- 13, has a 
role in increasing the differentiation of eosinophils at a point “upstream” to that 
of IL-5. Although the source of IL-5 and IL-33 within the bone marrow neces-
sary for the development of eosinophils is not known exactly, it is likely that T 
cells and certain innate lymphoid cells (CLI2) are the important sources, at least 
for IL-5. [2]
3. Beneficial functions of eosinophils in homeostasis and host defense
Most of what is known about eosinophils in terms of their roles in health and 
homeostasis, comes from data obtained from animal studies. It is believed that 
eosinophils contribute a large amount of beneficial substances that help in the 
development, remodeling, and tissue repair. Their roles in innate and adaptive 
immune responses include the favorable influence on the development of immune 
cells, provide antibacterial, antifungal, and antiviral responses and help control 
glucose metabolism, myocyte regeneration, lean fat development and adipos-
ity. Most of these functions have been demonstrated in animal models, so their 
reality in humans is uncertain. In addition, although the very important role of 
eosinophils during type 2 immune responses against helminths and other para-
sitic infections is considered almost dogmatic, their total certainty in humans is 
controversial because in many patients in pandemic parasitic infections we know 
have increase eosinophils and we do not the normal range in laboratory test and 
the main changes that decreasing of increasing (Figure 2). Therefore, despite the 
growing interest in knowing what eosinophils actually in the immune system and 
in disease circumstance, in the nest days we need to know and much remains to be 
investigated. [3]
Figure 2. 
The eosinophil cycle and function.
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4. Asthma and COPD
COPD and asthma have a pathogenic and pathophysiological basis easily dif-
ferentiable in most cases. They also share a series of clinical similarities that often 
make their differentiation complex, especially in-patient smokers with a history 
of atopy and eosinophilia. But we have patients with combined symptoms and 
different phenotypic. The characteristics clinics shared by both diseases are based 
on inflammation and airway obstruction, now we know in certain papers that 
COPD is a fibrotic disease but when the patient have some allergic characteristics 
the disease is like an inflammatory problem and the eosinophils have a role in both. 
The incomplete reversible and progressive in COPD and variable and reversible 
in asthma. Also, the location of the inflammatory response in these pathologies 
also have differences, allowing to locate the predominant involvement of COPD 
in the peripheral airway and in the pulmonary parenchyma, in contrast to the 
respect of pulmonary parenchyma and panfocal airway involvement in asthma. 
The cell count obtained from bronchioalveolar lavage (BAL), induced sputum 
and bronchial biopsies in patients with COPD demonstrate the predominant 
presence of neutrophils, CD8 + T lymphocytes and abundant macrophages. In 
asthma, eosinophils, mast cells, CD4 + T cells and fewer macrophages meet in 
samples representative of the tracheobronchial tree, but there are some patients 
with paucigranulocitic phenotypic. Inflammatory mediators also differ, playing a 
predominant role leukotriene-B4 (LTB4), interleukin 8 (IL-8) and tumor necrosis 
factor alpha (TNF-α), among others, in the case of COPD, while in asthma have 
found multiple inflammatory variables, represented for histamine, leukotrienes 
and interleukins 4 and 5.
The fraction of exhaled nitric oxide in patients with asthma is found increased, 
reflecting the greater eosinophilic inflammation. Thus, it seems reasonable to 
define a high Th2 patient profile in a non-invasive way by using indirect markers 
such as IgE > 100 IU and blood eosinophils>300 cells/microliter, or eosinophils in 
sputum>3%. Along these lines, a recent study has shown that eosinophilia together 
with elevated levels of periostin was the best predictor of improvement in lung 
function in COPD patients treated for three months with inhaled corticosteroids 
and LABA. However, it seems that a more integrative approach, which unites 
clinical features and molecular mechanisms, is the best way to identify disease sub 
phenotypes and individualized treatments. The fraction of exhaled nitric oxide is 
poor studied in COPD, and we know there is not a confinable test to follow a patient 
we do not have inflammation or have both. [3]
5. Eosinophils and COPD
In December 2017, we published in the journal Respirar de ALAT, a manu-
script of the study findings of 50 Mexican patients in the outpatient pulmonology 
clinic at the University Hospital of Puebla, Mexico, the results were prevalence 
of eosinophilia (74% women and 26% men). 50% associated with smoking 
and 50% with exposure to biomass. 36% presented representative eosinophilia 
which indicated the relevance of this marker taking into account that 50% of 
all the patients studied were in GOLD IVD stage. Tine and colleagues pointed 
out that blood eosinophils may have a paradoxical benefit for COPD patients; In 
patients with blood eosinophil counts of 2% or more versus patients with counts 
of less than 2%, better lung function, better quality of life, fewer symptoms and 
less comorbidities have been reported. It has also been shown that the risk of 
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pneumonia, regardless of the use of inhaled steroids, is lower in patients with 
eosinophil blood counts of 2% or more. These facts suggest, the authors wrote, 
that the use of eosinophil-targeted therapies can actually be detrimental to COPD 
patients. [4–5].
6. Eosinophilic pathways in asthma
The Eosinophils nowadays are the most inflammatory status seen in asthma, in 
patients that have persistent eosinophilic airway inflammation is a severe status in 
some cases. Because these patients have neutrophilic or paucigranulocytic count 
and separate in allergic and nonallergic patients with severe symptoms. The path-
ways for eosinophil recruitment are quite distinct. Allergic eosinophilic asthma is 
driven by Th2 lymphocytes. Allergens, presented to naive CD4+ T cells by dendritic 
cells, induce differentiation toward Th2 cells, which produce IL4, IL5 and lead-
ing to IgE class to airway eosinophilia and mucous hypersecretion. In nonallergic 
eosinophilic asthma, epithelium-derived cytokines (IL25, IL33, TSLP) are released 
in response to air pollutants, microbes or glycolipids (Figure 3). These bind to 
receptors on type-2 innate lymphoid cells (ILC2s), activating them to produce the 
Th2-associated cytokines IL5 and IL13, which lead to eosinophilia, mucous hyper-
secretion and airway hyper-reactivity, in the majority of allergic asthma cases, the 
presence of eosinophils may be a secondary consequence of the allergic cascade that 
recruits them to the site of inflammation in the evolution of the disease. In some 
patients, however, particularly those with severe, non-allergic asthma the eosino-
phil may play a more central role, possibly initiating the disease or persistent disease 
or persistent symptoms, these patients are typically older women with comorbid 
nasal polyps, aspirin sensitivity and late-onset asthma concluded in a different 
phenotypic. [5]
Figure 3. 
Allergic and non-allergic eosinophilic pathways in asthma.
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7. Eosinophilic inflammation in COPD
In COPD, inflammation is more commonly associated with T helper 1 lympho-
cyte (Th1)-mediated immunity driven by neutrophils, often in response to bacterial 
colonization. However, as with asthma, COPD presents as a number of different 
clinical phenotypes and, in around 10–40% of patients, a degree of eosinophilic 
inflammation is present during stable state. We published some cases with severe 
COPD versus health patients in a asthma clinic in Puebla, and we describe that we 
do not know when is the time to take a eosinophils sample and make a different 
diagnosis in the clinic, the patients came to take a sample in stable state and have 
minor eosinophils cells like health people, and concluded like we need to know 
when is the better time to take a eosinophils sample. The cell senescence likely plays 
a pathophysiological role in COPD (Figure 4) particularly in relation to the release 
of cytokines other factors from senescent cells, many of which are also implicated in 
the pathogenesis of COPD [5].
8. The utility of measuring blood eosinophil levels in asthma and COPD
The most important point in this chapter is the utility of measuring blood 
eosinophils as a biomarker to treatment in stable or exacerbating COPD. Blood 
eosinophil levels can either be expressed as an absolute count (150 cells) or as a 
percentage, actually there are many groups that define them, like <2%, ≥2–<3%, 
≥3–<4%, <150 cells·μL − 1, 150–<300 cells·μL − 1, ≥300–<400 cells and ≥ 400 
cells were used in the post hoc analysis of WISDOM. 2020 guidelines from the 
Global Initiative for Chronic Obstructive Lung Disease (GOLD) have recommended 
blood eosinophil counts ≥300 cells in stable COPD as the diagnostic criterion for 
initiating therapy with ICS/long-acting β-agonist (LABA). However, eosinophilia 
is defined, the utility of the measurement is limited by the stability of the measure-
ment. People with COPD often start treatment with Dual Therapy (LABA/LAMA) 
some people use monotherapy in some patients, but in some group of patients 
continue use inhaled corticosteroids like added, sure measuring the number of 
Figure 4. 
Relationship between airway inflammation and bronchial abnormalities in COPD.
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eosinophils and concluded the people who will benefit with this kind of therapy. 
Some patients experience a worsening of their symptoms known as an exacerbation 
and the eosinophils maybe predict the risk of exacerbations that is so important for 
clinicians treating this patients, but there is a pooled analysis in 2020 with Singh et 
al. concluded that in a pooled analysis of 22,125 patients with COPD, do not find 
a clinically important relationship between baseline blood eosinophils count and 
exacerbation rate and is not a clinically useful predictor of future exacerbation risk, 
I think maybe we can use in worsening symptoms in a single time of the life of the 
patient, COPD is dynamic and heterogenic disease, maybe we can use in some cases 
in which the patient worsening symptoms. [6]
The utility of measuring blood eosinophils to guide therapy is likely to vary 
depending upon the clinical status of the patient, i.e. whether their COPD is stable, 
or they are experiencing an exacerbation. Now in press we have a manuscript that 
we can show in a cohort with severe COPD patients and healthy controls the blood 
eosinophils count do not change in a single sample and the count was similar in the 
same group in the same time. The evidence suggests that measuring, eosinophil 
levels to help guide therapy is useful with measuring eosinophils count to use ICS/
LABA, and reduction the use of inhaled corticosteroids y some patients that do not 
need this treatment. In COPD we need to consider the eosinophil count to choose 
treatment. [6]
9. We can use eosinophils like a target and biomarker in the biologics era
Anti-IL5 therapies are a great promise in patients with eosinophilic asthma, and 
we do not know if is the same to COPD, suggesting that depletion of eosinophils 
may not be a valid target in COPD. An initial study using the anti-IL5R antibody, 
benralizumab, in COPD patients with elevated baseline sputum eosinophils 
(≥3%) demonstrated numerical improvements in exacerbation rates, SGRQ-C 
and the self-administered Chronic Respiratory Questionnaire (CRQ-SAS) scores, 
and FEV1 (fraction exhalation volume in 1 second) however, these improvements 
were not statistically significant. Mepolizumab significantly reduced sputum and 
blood eosinophil counts compared with placebo in COPD patients with raised 
baseline eosinophils but, again, these differences did not translate into significant 
between-group differences in lung function parameters, exacerbation rates, and 
health-related quality of life. The role of eosinophils in COPD is complex and the 
benefits observed with ICS (inhaled Corticosteroids) are likely related to their 
effects on cells or pathways that do not involve eosinophils. These results suggest a 
potential role for eosinophilic airway inflammation on COPD exacerbations, but 
also clearly underline the fact that further studies are needed to refine the patients 
who may benefit from eosinophil-targeted treatments in COPD. The Benefit–risk 
ratio of ICS in patients with COPD based on blood eosinophil level in stable disease 
with increasing eosinophils counts, the use of ICS may offer increased benefit 
by reducing COPD exacerbations and always have precaution for development 
a pneumonia. ICS use in patients with lower eosinophils counts is potentially 
associated with decreased benefit and increased risk of pneumonia. Celli com-
ment that the possibility that an easily obtained biomarker such as peripheral 
blood eosinophil count may help determine a patient’s risk for certain outcomes 
and likelihood of responding to specific therapy is very appealing. However, as in 
many areas in life, “the devil is in the details”, and more data is needed before blood 
eosinophil levels can be used to identify a COPD phenotype amenable to specific 
 immunomodulatory therapy. [7]
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10. Variability of blood eosinophils as a biomarker in asthma and COPD
Peter G. Gibson et al. described to consider are those that lower the count and 
could lead to a false-negative test for diagnosis of the eosinophilic phenotype. These 
include eating, exercise, medications, and the time of testing. Consuming a light 
meal was found to reduce blood eosinophils between 2 and 4 h after eating, with an 
average 23% reduction at 4 h (from 130 to 100 cells/μL). Exercise also reduces blood 
eosinophil counts. For example, a symptom-limited exercise test in COPD patients 
reduced blood eosinophils at 2 h, with normalization by 24 h. In Puebla, Mexico 
in 2019 we compared two groups of patients in Asthma and COPD clinic, this two 
groups were: One group of severe COPD patients [6] and other group healthy sub-
jects [6] workers for the clinic, the age of the patient were 45–60 years and we found 
that the eosinophil count was similar in the COPD group and the control group. 
A study was carried out in the Asthma and COPD clinic of the City of Puebla in a 
Private Angeles Hospital, the presence of two groups of patients with COPD and 
another as a control group of health workers, and we obtained very interesting data 
from the account of the eosinophils in a stable state of the patients, since they came 
voluntarily on a normal and stable day to take the eosinophil count and what were 
our results: the following: 2 groups of patients with COPD 1 group with 6 patients 
and the second group with 8 healthy workers. The patients with COPD were severe 
but in a stable and controlled state and presented an eosinophil count between 144 
to 240 cells, and the group of health workers with an eosinophil range between 102 
and 192 cells. This finding in this small cohort of patients as a pilot study allows us 
to see that patients with severe COPD may have low eosinophil ranges because they 
are stable and controlled just like healthy workers and subsequently be able to use 
the eosinophil range in some exacerbation of patients who may present an increase 
in eosinophils and change the therapy, this small work carried out in a particular 
clinic allows us to conclude that serious patients who have a stable state really have 
eosinophils in the normal range and the increase of 300 cells is really a figure in 
which We can make changes in therapy, but on the other hand, in stable patients, 
it would not be appropriate to take hematic biometry in the stability consultations 
because it would not be case knowing that the eosinophil count remains normal and 
only in an exacerbation take them to determine changes in current therapeutics. We 
concluded that in asthma patients the eosinophil count is variable than the COPD 
patients. [8–10].
11.  What is the utility of eosinophils in two prevalent respiratory 
diseases today?
As described earlier in this chapter, eosinophils are in these times of progress in 
the treatment of asthma and COPD one of the important pillars at different stages 
of the disease, as described earlier, approximately 4 years ago we did not have a 
marker that we allow you to change our decisions in the therapy of these patients 
in the stable phase or in exacerbations, it seems that its use is very bleak in stable 
patients, but already established a little more scientific in its use in exacerbations, 
every patient shows us one of the possible use of eosinophils in the whole path of the 
disease either in a stable phase or in exacerbation. In the definition of the disease its 
integration is clearly not useful, as well as in the epidemiological phase, but not in 
the diagnostic phase where it can be important to emphasize the phenotypes in the 
two diseases such as in asthma: eosinophilic asthma and in COPD as eosinophilic 
COPD. In the clinic it has not contributed great importance and we do not think 
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it is relevant to know eosinophilia to determine if it is asthma or COPD even the 
spirometry is still the most important pillar of the diagnosis. in the classification of 
the disease it is of the utmost importance to determine if it is stable or exacerbated, 
as well as in the treatment that is vital to start steroid treatment, we know in asthma 
it is the pillar treatment of the disease not so in COPD but it allows to differentiate 
those responders to corticosteroids. Eosinophils at present and thanks to studies we 
can clearly establish its use at the beginning of the use of some biological medica-
tion to those patients with severe or exacerbated disease, as you know the exacerba-
tions are those that deteriorate the disease and give a poor prognosis. As biomarker 
for biological initiation it is vital, as it has also been demonstrated in its use in the 
follow-up of patients, as part of the response to the treatment already established. 
There are still unknowns about the use of these cells in stable patients, we are 
developing a writing of the results of a pilot work on the values of eosinophils in 
stable patients with serious disease and healthy patients, these results will be shortly 
where we can show that in the stable patient there is still controversy in the use of 
treatment in patients with eosinophilia. [10]
12. Conclusion
Asthma and COPD are two chronic diseases linked to exacerbations and possible 
quality of life of patients, the introduction of eosinophils as biomarkers in the evolu-
tion of the disease has opened a promising panorama as a biomarker in the classifica-
tion of patients, their severity, prognosis and presence of exacerbations. Eosinophilia 
in these diseases is a reality and as pulmonologists we have a duty to always carry 
out that scrutiny that allows us to characterize our patients and to prescribe the 
appropriate treatment always taking into account the possible use of biologists in 
patients with severe disease. Both asthma and COPD are complex, heterogeneous 
conditions comprising a wide range of phenotypes, some of which are refractory to 
currently available treatments. These phenotypes and identification of biomarkers 
with which to recognize to guide an appropriate treatment for researchers and clini-
cians. The potential of blood eosinophils nowadays has potential and much attention 
in medical research to choose the optimal and correct treatment. In asthma, the 
rationale for their use as such is more clearly defined, with several well-controlled 
studies demonstrating that patients with higher eosinophil counts are prone to more 
severe disease and poorer outcomes. As a result, new biologic therapies have been 
developed to tailor treatment to these patients. In COPD, high blood eosinophil 
counts may predict a favorable response to ICS on top of LABA/LAMA, especially 
in patients with a history of frequent exacerbations, but the exact position and the 
definition of clinically significant eosinophilia is need to be more studied for the use 
of blood eosinophils for the identification of patients who may benefit from targeted 
treatments (Table 1). the use of eosinophils in clinical practice in COPD needs to 
be evaluated in prospective studies before firm conclusion and demonstrated in 
stable patients. [10] Eosinophilic inflammation is a stable longitudinal phenotype in 
a substantial proportion of COPD patients, which can be predicted over 12 months 
by an initial blood level measurement. The need for biomarkers to identify patients 
who may benefit from treatments in airways disease. As more treatment options are 
becoming available, we need to research and choose the biomarkers like elements 
or activation states of eosinophilic inflammation and will support the selection of 
treatment we need to control the patient in asthma and COPD. These events are 
seasonal in nature and relate to bacterial etiology and considerate the weather to take 
the sample. [11]
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Utility Asthma COPD
In definition − −
In epidemiological decision −/+ −
In diagnosis +/− −
In clinic + +
In classification + −
In exacerbations + +
In treatment ++ ++




Utility of eosinophil as a biomarker in clinic.
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